GMS | 22nd Annual Meeting of the German Drug Utilisation Research Group (GAA)

Kaumanns K, Kastenmüller K, Coch C, von Mallek D, Leuchs AK, Benda N, Meier F, Schöffski O, Holdenrieder S, Hartmann G, Weckbecker K, Stingl J
[Full Text]

Meeting Abstract (15gaa08)

KAMPI – Project to promote evidence-based drug information in German hospital pharmacies

Gruber AC, Amann S, Mildner C, Querbach C, Schuhmacher C, Strobach D, Vetter-Kerkhoff C
[Full Text]

Meeting Abstract (15gaa09)

Medication safety – Risk of statin-induced myopathie

Farker K, Leichenberg K, Hartmann M
[Full Text]

Meeting Abstract (15gaa10)

Morbidity Related Groups (MRG) and drug economic efficiency index – a new concept after the age of "Richtgrößen" benchmarks in Germany.

Schuster R
[Full Text]

Meeting Abstract (15gaa11)

Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice

Schedlowski M
[Full Text]

Meeting Abstract (15gaa12)

Physicians ask Pharmacists – Analysis of enquiries answered by the drug information service of the pharmacy in a university hospital 2005–2014

Vetter-Kerkhoff C, Lachenmayr S, Kufeldt J, Andraschko M, Strobach D
[Full Text]

Meeting Abstract (15gaa13)

Polypharmacy in Germany: Results of the German National Health Interview and Examination Survey 1998 (GNHIES 1998) and the German Health Interview and Examination Survey for Adults Wave 1 (DEGS1, 2008–2011)

Knopf H
[Full Text]

Meeting Abstract (15gaa14)

Potentially Inappropriate Medications (PIM) in the acute inpatient geriatric institution of the university hospital in Jena/Thuringia

Al-Otti S, Kwetkat A, Hippius M
[Full Text]

Meeting Abstract (15gaa15)

Private prescriptions of benzodiazepines and Z-drugs for statutory health insurance patients

Puteanus U, Beigi A, Rueter T, Hempel G
[Full Text]

Meeting Abstract (15gaa16)

Rationale Pharmakotherapie bei Patienten mit Diabetes mellitus Typ 2

Luebeck R, Karimova K, Hammer M, Guenthlin C, Beyer M
[Full Text]

Meeting Abstract (15gaa17)

The Early Benefit Assessment and the Single Technology Appraisal from NICE – comparison of the HTA methods and their influence on prescribing practice

Lämmel J, Maywald U, Knoth H, Schmitt J, Nagels K
[Full Text]

Meeting Abstract (15gaa18)

Therapy of Hepatitis C: embracing change

Langner I, Selke GW, Eichler U
[Full Text]

Meeting Abstract (15gaa19)

VKA vs. NOAC advantages in application-related patient safety

Krek C, Grave B, Heeke A
[Full Text]

Meeting Abstract (15gaa20)

Why do family doctors prescribe potentially inappropriate medication to elderly patients?

Voigt K, Gottschall M, Köberlein-Neu J, Bergmann A
[Full Text]

gms | German Medical Science

22nd Annual Meeting of the German Drug Utilisation Research Group (GAA)

Abstracts

Acceptability and feasibility of the medication plan vs. 2.0 in the model region of Erfurt: a prospective cohort study

Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study

Can claims data help validating drug risk signals? A case report

Comparative evaluation of methods approximating drug prescription durations in claims data: Modeling, simulation, and application to real data

DOACs – whom for? Secondary data analysis of current prescription trends

Graph theoretic analysis of neighbourhood relations with respect to simultaneously applied drugs

Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – a pragmatic trial in individualized medicine